大阪大学 · 医学
高橋茂義教授の研究室は、糖尿病の病態メカニズムとその治療戦略の解明を柱としています。特に、動脈硬化性閉塞性疾患を伴う下肢閉塞性動脈疾患（CLI）患者における血糖制御の影響や、SGLT2阻害薬がβ細胞機能に与える影響を臨床的・生化学的に解明しています。また、日本人におけるinsulin sensitivityの評価指標としてのMatsuda Indexの臨床的有用性の検討も進めています。
Figures are computed from collected data and may differ slightly.
Diabetes with poor glycemic control is associated with major amputation, but not mortality, in CLI patients undergoing PTA. Prognostic indicators seem somewhat different between survival and limb salvage in the population.
It remains to be seen whether pancreatic β cell dysfunction in type 2 diabetic patients can be ameliorated just by correcting hyperglycemia. The current pilot study investigated β cell function after a four-week treatment with a sodium-glucose cotransporter 2 (SGLT2) inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. Ten participants (age, 51±13 years; hemoglobin A1c levels, 9.4±1.0%) took 50 mg of ipragliflozin L-proline for four weeks and thereafter discontinued the ag
We investigated the cut-off point of the Matsuda Index in Japanese according to the guideline from the Clinical and Laboratory Standards Institute. A total of 1,596 subjects free from medications for diabetes mellitus, dyslipidemia and/or hypertension, and without cardiovascular diseases or chronic renal failure underwent a health check-up and oral glucose tolerance test (OGTT). We recruited 204 healthy reference individuals with normal glucose tolerance without obesity, any component of metabol
Open papers in the app to read, cite, and organize with AI.
